Lanreotide autogel 120 mg

DRUG4 trials

Sponsors

Ipsen

Conditions

AcromegalyGastroenteropancreatic Neuroendocrine TumorsMidgut Neuroendocrine TumoursPancreatic Tumours

Phase 2

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

CompletedNCT02231762

IpsenGastroenteropancreatic Neuroendocrine Tumors

Start: 2014-10-31End: 2017-06-30Updated: 2019-05-06

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

CompletedNCT02651987

IpsenMidgut Neuroendocrine Tumours, Pancreatic Tumours

Start: 2015-12-15End: 2019-10-24Updated: 2022-10-03

Phase 3

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

CompletedNCT00690898

IpsenAcromegaly

Start: 2008-05-31End: 2012-02-29Updated: 2022-10-14

Phase 4

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

CompletedNCT00701363

IpsenAcromegaly

Start: 2008-10-31End: 2013-05-31Updated: 2019-01-29

Related Papers

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study

The Oncologist2024-01-116 citations

Use of Oral Concomitant Medications in Patients With Acromegaly

Journal of the Endocrine Society2021-05-011 citations

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

Pituitary2019-12-2644 citations

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Pituitary2015-11-2442 citations